Results of Operations and Financial Condition

Filing summary

Seaport Therapeutics, Inc. furnished a Form 8-K dated November 2, 2026, reporting that it announced financial results for the quarter ended September 30, 2026. The filing identifies the company as a Delaware corporation listed on Nasdaq under ticker SPTX.

Financial results

The supplied filing text does not include the results or financial statements. It refers to a November 2, 2026 press release as Exhibit 99.1, but the exhibit’s contents are not provided here. Revenue, profit or loss, cash flow, margins, debt, liquidity, and other financial metrics therefore cannot be determined from this text.

Changes, outlook, and risks

The supplied text contains no comparison with the prior period, guidance, management commentary, risk updates, contingencies, or unusual items beyond the announcement of quarterly results.

Important facts to verify

  • Obtain Exhibit 99.1 to review the reported quarter’s financial results and management commentary.
  • Compare the quarter ended September 30, 2026, with the prior comparable period and assess cash, cash runway, and any stated outlook or risks.
  • The company checked the box identifying itself as an emerging growth company.

The company stated that the information in the 8-K and its exhibit was furnished, not filed for purposes of Section 18 of the Exchange Act, and is not incorporated by reference except where expressly specified.

Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.